Literature DB >> 27426417

Determinants of low levels of brain natriuretic peptide in morbid obesity.

Maria Anastasia Ricci1, Stefano De Vuono1, Giacomo Pucci2, Francesco Di Filippo1, Sokol Berisha1, Alessandra Gentili1, Giulia Daviddi1, Stefano Ministrini1, Fabio Rondelli3, Marcello Boni3, Graziana Lupattelli4.   

Abstract

BACKGROUND & AIMS: morbid obesity is associated with cardiovascular comorbidity. A noteworthy feature of this relationship could regard low levels of brain natriuretic peptide (BNP). The study investigates the relationship between BNP and obesity-related markers in a morbid obese population, along with echocardiographic and vascular parameters.
METHODS: in 154 morbid obese patients we evaluated anthropometric parameters, glycometabolic/lipid profile, bioimpedentiometry, echocardiography, visceral fat area and flow-mediated dilation (FMD) by ultrasonography.
RESULTS: we divided population in two groups on the basis of median BMI levels; patients with higher BMI had significantly lower BNP (p = .008), FMD (p = .014) and HDL-C (p = .001) and showed a more impaired heart function. A similar trend emerged subdividing patients on the basis of median visceral fat area. BNP showed a significant inverse correlation with BMI (p < .001), left ventricular mass (p = .026) and inter-ventricular septum thickness (p = .007) and a significant positive correlation with FMD (p = .008), HDL-C (p = .022), and ejection fraction (p = .013). BMI and triglycerides were independent predictors of BNP levels.
CONCLUSIONS: patients with higher BMI show lower BNP levels associated with greater total body fat amount. The correlation of BNP with endothelium-dependent vasodilation and cardiac impairment could represent another link between obesity and cardiovascular damage.
Copyright © 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Brain natriuretic peptide; Endothelial dysfunction; Morbid obesity; Obesity cardiomyopathy

Mesh:

Substances:

Year:  2016        PMID: 27426417     DOI: 10.1016/j.clnu.2016.06.024

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  5 in total

1.  Effect of various weight loss interventions on serum NT-proBNP concentration in severe obese subjects without clinical manifest heart failure.

Authors:  Tim Hollstein; Kristina Schlicht; Laura Krause; Stefanie Hagen; Nathalie Rohmann; Dominik M Schulte; Kathrin Türk; Alexia Beckmann; Markus Ahrens; Andre Franke; Stefan Schreiber; Thomas Becker; Jan Beckmann; Matthias Laudes
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

2.  Short term variation in NTproBNP after lifestyle intervention in severe obesity.

Authors:  Debora Fedele; Virginia Bicchiega; Alessandro Collo; Federica Barutta; Erika Pistone; Gabriella Gruden; Graziella Bruno
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

3.  NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study.

Authors:  Stefano Baldassarre; Salvatore Fragapani; Antonio Panero; Debora Fedele; Silvia Pinach; Manuela Lucchiari; Anna Rita Vitale; Giulio Mengozzi; Gabriella Gruden; Graziella Bruno
Journal:  Cardiovasc Diabetol       Date:  2017-09-25       Impact factor: 9.951

4.  Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis.

Authors:  Francesco Spannella; Federico Giulietti; Marica Bordicchia; John C Burnett; Riccardo Sarzani
Journal:  Sci Rep       Date:  2019-12-16       Impact factor: 4.379

5.  Joint Associations of Obesity and NT-proBNP With the Incidence of Atrial Fibrillation in the ARIC Study.

Authors:  Zakaria Almuwaqqat; Wesley T O'Neal; Faye L Norby; Pamela L Lutsey; Elizabeth Selvin; Elsayed Z Soliman; Lin Y Chen; Alvaro Alonso
Journal:  J Am Heart Assoc       Date:  2019-09-28       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.